Sections
| Title | Starting Page | Number of Pages |
|---|
| Table of Contents | 4 | 7 |
| List of Tables | 7 | 2 |
| List of Figures | 9 | 2 |
| Diabetes Therapeutics Market to 2017 - Introduction | 11 | 2 |
| GBI Research Report Guidance | 12 | 1 |
| Diabetes Therapeutics Market to 2017 - Market Overview | 13 | 15 |
| Introduction | 13 | 1 |
| Three Major Unmet Needs Prevalent in the Diabetes Market | 13 | 1 |
| Complications like Heart Risks are Associated with Some of the Oral Anti-Diabetic Drugs | 13 | 1 |
| Patients on Insulin Analogues are Prone to Carcinogenic Effects | 14 | 1 |
| Poor Patient Compliance with Anti-Diabetic Drug Therapy | 14 | 1 |
| Revenue | 15 | 2 |
| Annual Cost of Therapy (ACT) | 17 | 2 |
| Treatment Usage Patterns | 19 | 2 |
| Prevalence Population | 21 | 1 |
| Treatment Seeking Population | 22 | 1 |
| Diagnosed Population | 23 | 1 |
| Prescription Population | 24 | 1 |
| Drivers and Restraints of the Diabetes Therapeutics Market | 25 | 1 |
| Drivers of the Diabetes Market | 25 | 1 |
| Promising Molecules in the Pipeline for the Treatment of Diabetes | 25 | 1 |
| Significant Increase in the Prescription of Peptide Analogues | 25 | 1 |
| Sedentary Lifestyles and Obesity to Increase Diabetes Prevalence | 25 | 1 |
| Increase in Prevalence Population and Treatment Seeking Population | 26 | 1 |
| Restraints for the Diabetes Market | 26 | 1 |
| Complications and Side Effects Affecting Sales of Anti-Diabetic Drugs | 26 | 1 |
| Patent Expiry of Drugs such as Actos, Starlix and Avandia is Expected to Restrain the Growth of the Global Diabetes Market | 26 | 1 |
| Branded vs. Generic Market Share in the Global Diabetes Market | 27 | 1 |
| Diabetes Therapeutics Market to 2017 - Geographical Landscape | 28 | 25 |
| The US | 28 | 1 |
| Revenue | 28 | 2 |
| Annual Cost of Therapy | 30 | 1 |
| Treatment Usage Patterns | 31 | 2 |
| Prevalence Population | 33 | 1 |
| Treatment Seeking Population | 34 | 1 |
| Diagnosed Population | 35 | 1 |
| Prescription Population | 36 | 1 |
| Top Five Countries of Europe | 37 | 1 |
| Revenue | 37 | 2 |
| Annual Cost of Therapy | 39 | 1 |
| Treatment Usage Patterns | 40 | 2 |
| Prevalence Population | 42 | 1 |
| Treatment Seeking Population | 43 | 1 |
| Diagnosed Population | 44 | 1 |
| Prescription Population | 45 | 1 |
| Japan | 46 | 1 |
| Revenue | 46 | 1 |
| Annual Cost of Therapy | 47 | 1 |
| Treatment Usage Patterns | 48 | 1 |
| Prevalence Population | 49 | 1 |
| Treatment Seeking Population | 50 | 1 |
| Diagnosed Population | 51 | 1 |
| Prescription Population | 52 | 1 |
| Diabetes Therapeutics Market to 2017 - Therapeutic Landscape | 53 | 28 |
| Type 1 Diabetes Market | 53 | 1 |
| Introduction | 53 | 1 |
| Symptoms | 53 | 1 |
| Treatment | 53 | 2 |
| Unmet Needs | 55 | 1 |
| Branded vs. Generic Market Share in the Type 1 Diabetes Market | 56 | 1 |
| Revenue | 57 | 1 |
| Annual Cost of Therapy (ACT) | 58 | 2 |
| Treatment Flow Algorithm for Type 1 Diabetes | 60 | 1 |
| Treatment Usage Patterns | 61 | 1 |
| Prevalence Population | 62 | 1 |
| Treatment Seeking Population | 62 | 2 |
| Diagnosed Population | 64 | 1 |
| Prescription Population | 65 | 1 |
| Drivers and Restraints for the Type 1 Diabetes Market | 66 | 1 |
| Drivers for the Type 1 Diabetes Market | 66 | 1 |
| Restraints for the Type 1 Diabetes Market | 67 | 1 |
| Type 2 Diabetes Market | 68 | 1 |
| Introduction | 68 | 1 |
| Symptoms | 68 | 1 |
| Treatment | 68 | 1 |
| Unmet Needs | 68 | 2 |
| Branded vs. Generic Market Share in the Type 2 Diabetes Market | 70 | 1 |
| Revenue | 70 | 2 |
| Annual Cost of Therapy | 72 | 1 |
| Treatment Flow Algorithm for Type 2 Diabetes | 73 | 1 |
| Treatment Usage Patterns | 74 | 1 |
| Prevalence Population | 75 | 1 |
| Treatment Seeking Population | 76 | 1 |
| Diagnosed Population | 77 | 1 |
| Prescription Population | 78 | 1 |
| Drivers and Restraints for the Type 2 Diabetes Market | 79 | 1 |
| Drivers for the Type 2 Diabetes Market | 79 | 1 |
| Restraints for the Type 2 Diabetes Market | 80 | 1 |
| Diabetes Therapeutics Market to 2017 - Pipeline Analysis | 81 | 30 |
| Introduction | 81 | 1 |
| Research and Development Pipeline - Type 1 Diabetes | 82 | 7 |
| Research and Development Pipeline - Type 2 Diabetes | 89 | 11 |
| Innovations in Diabetes Treatment | 100 | 1 |
| Insulin in Pills (Oral Delivery) | 100 | 1 |
| Promising Treatments for Diabetic Retinopathy | 100 | 1 |
| Biomarkers in Diabetes | 100 | 1 |
| Combination Drugs are an Important Part of the Diabetes Pipeline | 101 | 1 |
| Cellular Activation Therapy (CAT) | 101 | 1 |
| Drug Delivery in Diabetes | 102 | 1 |
| Factors Determining Preference for Drug Delivery | 102 | 1 |
| Desirable Drug Delivery Methods for Diabetes which are Currently Unavailable | 102 | 1 |
| Innovation in Drug Delivery Systems | 102 | 1 |
| Transdermal Passport System | 102 | 1 |
| Encapsulation Systems U-Strip Insulin System | 103 | 1 |
| Technosphere Insulin System | 103 | 1 |
| Profiles of Promising Drugs in the Diabetes Market | 104 | 1 |
| rhGAD65 (Diamyd) | 104 | 1 |
| Bydureon | 104 | 1 |
| DiaPep277 | 105 | 1 |
| Otelixizumab | 106 | 1 |
| Alogliptin | 106 | 1 |
| Oral-Lyn | 107 | 1 |
| Dapagliflozin | 108 | 1 |
| Canagliflozin | 109 | 1 |
| MB07803 | 110 | 1 |
| Diabetes Therapeutics Market to 2017 - Competitive Landscape | 111 | 35 |
| Diabetes Market Overview | 111 | 1 |
| Human Insulin Products and Oral Antidiabetic Drugs like Actos Group (Actos and Actoplus Met) and Lantus Have Led Market Growth | 111 | 1 |
| Market Share Analysis - Diabetes | 112 | 1 |
| Market Share Analysis by Company - 2010 | 112 | 1 |
| Market Share Analysis by Company - 2017 | 113 | 1 |
| Market Share Analysis by Class for the Anti-Diabetic Drugs | 114 | 1 |
| Market Share Analysis by Drug Class - 2010 | 114 | 1 |
| Market Share Analysis by Drug Class - 2017 | 115 | 1 |
| Competitive Profiling | 116 | 1 |
| Novo Nordisk | 116 | 1 |
| Product Portfolio | 117 | 1 |
| Marketed Drugs Profile | 117 | 3 |
| Product Pipeline | 120 | 1 |
| SWOT Analysis | 120 | 1 |
| Sanofi | 121 | 1 |
| Product Portfolio | 122 | 1 |
| Marketed Drugs Profiles | 123 | 2 |
| Product Pipeline | 125 | 1 |
| SWOT Analysis | 125 | 1 |
| Takeda | 126 | 1 |
| Product Portfolio | 126 | 1 |
| Marketed Drugs Profiles | 127 | 1 |
| Product Pipeline | 128 | 1 |
| SWOT Analysis | 128 | 1 |
| Eli Lilly | 129 | 1 |
| Product Portfolio | 130 | 1 |
| Marketed Drug Profiles | 131 | 3 |
| Product Pipeline | 134 | 1 |
| SWOT Analysis | 134 | 1 |
| GlaxoSmithKline (GSK) | 135 | 1 |
| Product Portfolio | 136 | 1 |
| Marketed Drugs Profiles | 136 | 2 |
| Product Pipeline | 138 | 1 |
| SWOT Analysis | 138 | 1 |
| Merck &Co Inc | 139 | 1 |
| Product Portfolio | 140 | 1 |
| Marketed Drugs Profile | 140 | 1 |
| Product Pipeline | 141 | 1 |
| SWOT Analysis | 141 | 1 |
| Amylin Pharmaceuticals | 142 | 1 |
| Product Portfolio | 143 | 1 |
| Marketed Drugs Profiles | 144 | 1 |
| Product Pipeline | 144 | 1 |
| SWOT Analysis | 145 | 1 |
| Diabetes Therapeutics Market to 2017 - M&A Landscape | 146 | 17 |
| Overview | 146 | 2 |
| Mergers and Acquisitions (M&A) | 148 | 1 |
| Strategic Consolidation | 148 | 1 |
| M&A Deals by Value | 149 | 1 |
| Major Mergers and Acquisitions | 150 | 1 |
| M&A Deals by Geography | 151 | 1 |
| M&A Deals by Indication | 152 | 1 |
| Licensing Agreements | 153 | 1 |
| Licensing by Geography | 153 | 1 |
| Major Licensing Agreements | 154 | 2 |
| Licensing Agreements by Indication | 156 | 1 |
| Licensing Agreements by Value | 157 | 1 |
| Co-Development | 158 | 1 |
| Co-Development by Geography | 158 | 1 |
| Major Co-Development Deals | 159 | 2 |
| Co-Development by Indication | 161 | 1 |
| Co-Development by Value | 162 | 1 |
| Diabetes Therapeutics Market to 2017 - Appendix | 163 | 6 |
| Market Definitions | 163 | 1 |
| Abbreviations | 163 | 1 |
| Research Methodology | 163 | 5 |
| Coverage | 164 | 1 |
| Secondary Research | 164 | 1 |
| Primary Research | 165 | 1 |
| Forecasts | 165 | 1 |
| Epidemiology-based Forecasting | 165 | 2 |
| Expert Panel Validation | 167 | 1 |
| Contact Us | 168 | 1 |
| Disclaimer | 168 | 1 |
| Sources | 168 | 1 |